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Dextromethorphan (DM) administered at supra-antitussive doses produce psychotoxic and neurotoxic
effects in humans. We administered DM (80 mg/kg) to rats intraperitoneally to determine the ultra-
structural change induced by DM, because intraperitoneal route is sensitive for the behavioral responses.
Treatment with DM resulted in mitochondrial dysfunction and formation of myelinoid bodies in the
hippocampus. MK-801 [(þ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate]
attenuated DM-induced cytosolic oxidative burdens. However, neither MK-801 nor naloxone affected
DM-induced mitochondrial dysfunction and formation of myelinoid bodies, indicating that the neuro-
toxic mechanism needs to be further elucidated. Therefore, the spectrum of toxicological effects asso-
ciated with DM need to be reassessed.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Dextromethorphan (DM, 3-methoxy-17-methylmorphinan) is a
dextrorotatory optical isomer of levomethorphan, a typical
morphine-like opioid. With increasing DM doses, the user experi-
ences dysmetria and an inability to respond to pain and other
external stimuli (1). Five teenagers who ingested large doses of DM
that they obtained over the internet for recreational purposes died
as a result of its direct toxic effects (2). Fatal poisonings due to large
amounts of DM and zipeprol have been reported in Korea (3).
Within an antitussive dose range, DM is an effective cough sup-
pressant with negligible side effects; however, at very high doses,
DM produces a very complex pharmacological proﬁle (2, 4e6)..
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d/4.0/).An earlier report showed that a single exposure to a non-
competitive N-methyl-D-aspartate (NMDA) receptor antagonist,
MK-801, produced vacuolar degeneration in the posterior cingulate
cortex and the retrosplenial cortex in the rat brain (7). In contrast,
another NMDA receptor antagonist, DM, did not produce neuro-
pathologic changes when administered orally (8). Therefore, we
investigatedwhether DM induces neuropathological changes in the
brain when taken via the i.p. route. Because DM binding sites are
mainly located in the CA1 area of the hippocampus (9), herein, we
focused on the CA1 region. Unexpectedly, we observed that DM
produces myelinoid bodies with a concentrically laminated mem-
brane in the CA1 region of the rat hippocampus. Since Miao et al.
(10) suggested that formation of myelinoid bodies might be related
to mitochondrial degeneration, we investigated whether DM pro-
duces mitochondrial dysfunction in the present study.
Rats received 80 mg/kg, i.p. of DM, and then were sacriﬁced 1
day later (Fig. 1A). Rats were anesthetized with sodiumnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Experimental design for evaluating DM-induced ultrastructural changes; effects of naloxone or MK-801 on DM (80 mg/kg, i.p.)-induced formation of myelinoid bodies (A),
and representative photomicrographs of ultrastructural changes in the CA1 area of the hippocampus from rats in the presence of DM (B); Saline-treated animal showed a well-
preserved ultrastructural architecture (a). DM (80 mg/kg, i.p.)-induced ultrastructural changes in the neuropil around capillaries (b), and mitochondria (d; open arrow). Myeli-
noid bodies (b and c; closed arrows) were seen in the processes close to vessels in the hippocampus one day after DM administration. Cap ¼ capillary.
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2.5% glutaraldehyde in 0.1 M phosphate-buffer (PB, pH 7.4). The
hippocampal tissues were cut into small pieces and ﬁxed in the
same solution for 4 h at 4 C and then they were washed overnight
in PB and post-ﬁxed in 1% osmium tetroxide in PB for 1 h at 4 C.
The tissues were dehydrated in a graded series of acetone dilutions
and ﬁnally embedded in Epon 812 epoxidic resin. Ultra-thin sec-
tions (40 nm) were stained with uranyl acetate and lead citrate and
observed with a Philips EM400 transmission electron microscope
operating at 100 kV.We isolated cytosolic and mitochondrial fraction, and examined
lipid peroxidation reactive oxygen species as we previously
described (11). Mitochondrial transmembrane potential was
measured with the dye 5,50,6,60-tetrachloro-1,10,3,30-tetrae-
thylbenzimidazolycarbocyanine iodide (JC-1; Molecular Probes),
which exists as a green ﬂuorescent monomer at low membrane
potential, but reversibly forms red ﬂuorescent “J-aggregates” at
polarized mitochondrial potentials. Brieﬂy, aliquots of 250 mg of
isolated mitochondrial protein were suspended in respiration
buffer 250 mM sucrose, 20 mM HEPES, 2 mM MgCl2, 2.5 mM
Fig. 2. Effects of naloxone or MK-801 in response to DM (80 mg/kg, i.p.)-induced malondialdehyde (MDA) (A), and reactive oxidative species (B) in the cytosolic and mitochondrial
fraction of rat hippocampus. Each value is the mean ± S.E.M. of 6 animals. *P < 0.01 vs. Saline alone, #P < 0.05 vs. Saline þ DM (Two-way ANOVA followed by Fisher's LSD pairwise
comparisons).
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glutamate and 2.5 mM maleate gave similar results in all para-
digms) in a ﬁnal volume of 200 mL. The energized mitochondria
were then incubated at 37 in the presence of 10 mM JC-1 for
30min, after which ﬂuorescencewasmeasuredwith a ﬂuorometric
plate reader. The relative amount of mitochondrial polarization per
milligram of mitochondria was quantiﬁed by taking the ratio of
emission from 590 to 535 nm, respectively, with excitation at
500 nm (11). For assessment of intramitochondrial Ca2þ levels,
mitochondrial fractions (250 mg) were incubated in the presence of
the Ca2þ indicator rhod-2-AM (5 mM, Molecular Probes) for 60 min
at 37 C and washed three times with Ca2þ-free Locke's solution.
This reduced form of rhod-2-AM, is a colorless, nonﬂuorescent dye
that has a net positive charge, which promotes its sequestration
into mitochondria. The dye is then oxidized in the mitochondria
where the AM ester is cleaved, trapping the dye in the mitochon-
dria. Fluorescence was quantiﬁed with a ﬂuorometric plate reader
with excitation and emission wavelengths of 549 and 581 nm,
respectively (11).
Herein, we observed that a high dose of DM (80 mg/kg, i.p.)
produced ultrastructural neurodegenerative changes in thehippocampus. We observed that DM dose less than 80 mg/kg doses
not produce ultrastructural neurodegenerative changes, suggesting
that DM induced neurotoxic effects in a dose-related manner. In
this study, DM-induced neuropathologic features included myeli-
noid bodies with irregularities and swelling in the crista of hip-
pocampal mitochondria (Fig. 1B). Importantly, a major metabolite
of DM, dextrorphan (DX, 80 mg/kg, i.p.), did not induce the for-
mation of myelinoid bodies, suggesting that DM-mediated neuro-
toxic effects are independent of DX. In addition, subcutaneously or
orally administered high-dose DM did not form myelinoid bodies.
Previous report using rats demonstrated that maximal concentra-
tion of DM (i.p.) is higher than that of DM (s.c.), that behavioral
response induced by DM (60 mg/kg, s.c.) is signiﬁcantly lower than
that induced by DM (60 mg/kg, i.p.) (12), and that the formation of
DX and other metabolites is 3-fold greater after i.p. injection of
30 mg/kg of DM as compared to the s.c. route (12). These results
suggested that the administration route is important for DM-
mediated pharmaco-toxicological characteristics, and that un-
known mechanism may be involved in metabolic process after i.p.
injection with DM (5). Importantly, it is recognized that position-3
of 17 methylmorphinan molecules (i.e., DM and DX) is critical for
Fig. 3. Effects of naloxone or MK-801 in response to DM (80 mg/kg, i.p.)-induced
impairment in mitochondrial transmembrane potential (A) and intramitochondrial
Ca2þ accumulation (B) in the hippocampus of rats. *P < 0.01 vs. Saline alone (Two-way
ANOVA followed by Fisher's LSD pairwise comparisons).
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possesses hydroxy group at the position 3 as same as DX case,
although morphine produced myelinoid bodies. Thus, methoxy
group at the position 3 of 17 methylmorphinan (i.e., DM) molecules
may be not prerequisite for formation of myelinoid bodies.
Furthermore, morphine, DM and DX commonly possess methyl
group at the position 17. It remains to be determined on the role of
4,5-epoxy group in morphine molecule in producing myelinoid
bodies. Therefore, the structure-activity relationship between DM.
DX and morphine in terms of myelinoid body formation still re-
mains elusive (please refer to Supplementary Fig. 1).
Myelinoid bodies are common along large myelinated CNS ﬁ-
bers, and are also seen inside astrocytes and microglia, suggesting
that they might represent degenerating myelin quanta, involved in
the turnover of large myelin sheaths (14). Myelinoid bodies, which
are single membrane-bound lysosomal bodies, are currently
thought to be the product of metabolic defects or toxic cell damage
(10).
Miao et al. (10) demonstrated that morphine-induced formation
of myelinoid bodies is the primary ultrastructural alteration in lo-
cus coeruleus neurons of rats (although these phenomena remain
unknown in the hippocampus), and that their distinctive double-
membrane structure is recognizable in certain myelinoid bodies,
suggesting that these changes are derived from membrane rem-
nants of degenerated mitochondria. This ﬁnding suggests that
morphine treatment causes severe damage to mitochondria, which
induces cellular oxidation.
We found that the DM-induced appearance of myelinoid bodies
was the primary change in the processes of hippocampal cells; DM
formed myelinoid bodies in the CA1 ﬁeld, which is identiﬁed as aDM recognition site as well as a NMDA receptor distribution site
(9,15). Many of the regions with a moderate ability to bind to [3H]
DM have been directly implicated in seizure activity, and the
localization of [3H]DM binding in the hippocampus suggests that
the CA1 sector is one of the primary sites for the anticonvulsant
activity of DM (15).
Additionally, we observed that treatment with naloxone or MK-
801, does not affect DM-induced myelinoid body formation in the
hippocampus (Fig. 1A). MK-801 treatment signiﬁcantly attenuated
DM-induced cytosolic oxidative burdens, suggesting that high-dose
DM might play a role as a NMDA receptor agonist in an MK801-
sensitive manner, although NMDA receptor antagonistic potential
of optimal-dose DM might be comparable to that of MK-801.
However, MK-801 did not affect mitochondrial oxidative burdens
induced by DM (Fig. 2A and B). Neither naloxone nor MK-801
signiﬁcantly affected mitochondrial transmembrane potential
(Fig. 3A) and intra-mitochondrial Ca2þ level (Fig. 3B) induced by
DM. Therefore, DM-induced formation of myelinoid bodies does
not require the activation of opioid receptor or NMDA receptor.
Although underlying mechanism on this phenomenon remains to
be fully explored, we cannot rule out the possibility that DM may
form undigestible lipid complexes yielding lamellar inclusion
bodies (i.e., myelinoid bodies) and that these formations might
have certain functional relationship to the mitochondrial dysfunc-
tion (10).
In conclusion, we observed, for the ﬁrst time, that high-dose DM
produces neuropathologic features including myelinoid bodies and
irregularities in the crista of hippocampal mitochondria in the rat
brain. Neuropathologic features mediated by DMmay be, at least in
part, comparable to those mediated bymorphine (10). Therefore, in
light of safety concerns, it is necessary to reclarify the spectrum of
behavioral and toxicological side effects associated with adminis-
tration routes or neuroprotective doses of DM, although DM-
induced neurotoxicity only observed after intraperitoneal injec-
tion and it might be not feasible in human beings.Conﬂicts of interest
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